Pharma Journalist -

Abbott and Surmodics proclaimed having forayed into an agreement wherein Abbott will possess exclusive commercialization rights for Surmodic's Surveil drug-coated balloon to treat the…
Read More...

Longeveron asserted that its revolutionary Clinical Trial initiated to treat infants with Hypoplastic Left Heart Syndrome as the first patient received the treatment using the company's…
Read More...

Medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, Access Vascular asserted that the Company has sought …
Read More...

Eli Lilly and Company proclaimed that the USFood and Drug Administration has sanctioned Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based…
Read More...

PharmaCyte Biotech aiming to develop targeted cellular therapies for Cancer and diabetes using its signature  live-cell encapsulation technology, Cell-in-a-Box, announced that its…
Read More...

Vertex Pharmaceuticals asserted that Reshma Kewalramani, MD., has been appointed Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs,…
Read More...

Shionogi asserted that the NDA for lusutrombopag (S-888711), an investigational, once-daily, orally administered , small molecule thrombopoietin (TPO) receptor agonist, has been…
Read More...

Pharmaceutical company, Neumentum committed to transforming the way acute and chronic pain are treated-without  opioids asserted the confirmation of Type B meeting with the U.S FDA…
Read More...

Therapy combinations, Biomarkers and the challenge of prayer coverage for CAR T-cell therapy are the topics selected for this year's special tissue on immuno-oncology in  Evidence-Based…
Read More...

EpimAb Biotherapeutics which is essentially a biologics company based in Shanghai, China emphasizing on developing a portfolio of bispecific antibodies declared the appointment of Bin…
Read More...